FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Axworthy Don

Research Profile

Procedures

Living Beings

Chemicals & Drugs

Concepts & Ideas

Tissue Distribution

Disorders

Anatomy

Tumor Cell Line

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
John M Pagel; Anastasia Pantelias; Nathan Hedin; Shani Wilbur; Laura Saganic; Yukang Lin; Axworthy Don; Donald K Hamlin; D Scott Wilbur; Ajay K Gopal; Oliver W Press
Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.
Anastasia Pantelias; John M Pagel; Nathan Hedin; Laura Saganic; Shani Wilbur; Donald K Hamlin; D Scott Wilbur; Yukang Lin; Diane Stone; Axworthy Don; Ajay K Gopal; Oliver W Press
Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas.
John M Pagel; Yukang Lin; Nathan Hedin; Anastasia Pantelias; Axworthy Don; Diane Stone; Donald K Hamlin; D Scott Wilbur; Oliver W Press
Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Axworthy Don (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2007: John M Pagel; Anastasia Pantelias; Nathan Hedin; Shani Wilbur; Laura Saganic; Yukang Lin; Axworthy Don; Donald K Hamlin; D Scott Wilbur; Ajay K Gopal; Oliver W Press
Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.
Cancer research 2007;67(12):5921-8.
2007: Anastasia Pantelias; John M Pagel; Nathan Hedin; Laura Saganic; Shani Wilbur; Donald K Hamlin; D Scott Wilbur; Yukang Lin; Diane Stone; Axworthy Don; Ajay K Gopal; Oliver W Press
Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas.
Blood 2007;109(11):4980-7.
2006: John M Pagel; Yukang Lin; Nathan Hedin; Anastasia Pantelias; Axworthy Don; Diane Stone; Donald K Hamlin; D Scott Wilbur; Oliver W Press
Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.
Blood 2006;108(1):328-36.
2006: Yukang Lin; John M Pagel; Axworthy Don; Anastasia Pantelias; Nathan Hedin; Oliver W Press
A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.
Cancer research 2006;66(7):3884-92.
2005: Donald J Buchsbaum; Muhammad B Khazaeli; Axworthy Don; Jody Schultz; Tandra R Chaudhuri; Kurt R Zinn; Mark Carpenter; Albert F LoBuglio
Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(22):8180-5.
2005: Fu-Min Su; Paul Beaumier; Axworthy Don; Robert Atcher; Alan Fritzberg
Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Nuclear medicine and biology 2005;32(7):741-7.
2005: Andres Forero-Torres; Sui Shen; Hazel Breitz; Robert B Sims; Axworthy Don; Muhammad B Khazaeli; Kuang-Ho Chen; Ivor Percent; Stephen Besh; Albert F LoBuglio; Ruby F Meredith
Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.
Cancer biotherapy & radiopharmaceuticals 2005;20(4):379-90.
2005: Noriko Sato; Raffit Hassan; Axworthy Don; Karen J Wong; Sarah Yu; Louis J Theodore; Yukang Lin; Luke Park; Martin W Brechbiel; Ira Pastan; Chang H Paik; Jorge Carrasquillo
Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(7):1201-9.
2005: Kevin J Hamblett; Oliver W Press; Damon L Meyer; Donald K Hamlin; Axworthy Don; D Scott Wilbur; Patrick S Stayton
Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.
Bioconjugate chemistry 2005;16(1):131-8.
2004: Andres Forero; Paul L Weiden; Julie M Vose; Susan J Knox; Albert F LoBuglio; Jordan Hankins; Michael L Goris; Vincent J Picozzi; Axworthy Don; Hazel Breitz; Robert B Sims; Richard G Ghalie; Sui Shen; Ruby F Meredith
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Blood 2004;104(1):227-36.
2004: Nai-Kong V Cheung; Shakeel Modak; Yukang Lin; Hongfen Guo; Pat Zanzonico; John Chung; Yuting Zuo; James Sanderson; Sibylle Wilbert; Louis J Theodore; Axworthy Don; Steven M Larson
Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2004;45(5):867-77.
2004: Zhengsheng Yao; Meili Zhang; Kayhan Garmestani; Axworthy Don; Robert W Mallett; Alan R Fritzberg; Louis J Theodore; Paul S Plascjak; William Eckelman; Thomas Waldmann; Ira Pastan; Chang H Paik; Martin W Brechbiel; Jorge Carrasquillo
Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(9):3137-46.
2004: Michael R Lewis; Jiuli Zhang; Fang Jia; Nellie K Owen; Cathy S Cutler; Mary F Embree; Jody Schultz; Louis J Theodore; Alan R Ketring; Silvia S Jurisson; Axworthy Don
Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice.
Nuclear medicine and biology 2004;31(2):213-23.
2003: Scott S Graves; Erica Dearstyne; Yukang Lin; Yuting Zuo; James Sanderson; Jody Schultz; Anastasia Pantalias; David Gray; Axworthy Don; Hilary Jones; Karen Auditore-Hargreaves
Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3712-21.
2003: Michael R Lewis; Mu Wang; Axworthy Don; Louis J Theodore; Robert W Mallet; Alan R Fritzberg; Michael J Welch; Carolyn J Anderson
In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(8):1284-92.
2003: John M Pagel; Nathan Hedin; Krishnan Subbiah; Damon Meyer; Robert Mallet; Axworthy Don; Louis J Theodore; D Scott Wilbur; Dana C Matthews; Oliver W Press
Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.
Blood 2003;101(6):2340-8.
2003: Krishnan Subbiah; Donald K Hamlin; John M Pagel; D Scott Wilbur; Damon L Meyer; Axworthy Don; Robert W Mallett; Louis J Theodore; Patrick S Stayton; Oliver W Press
Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(3):437-45.
2003: Meili Zhang; Zhuo Zhang; Kayhan Garmestani; Jody Schultz; Axworthy Don; Carolyn K Goldman; Martin W Brechbiel; Jorge Carrasquillo; Thomas Waldmann
Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(4):1891-5.
2002: Zhengsheng Yao; Meili Zhang; Axworthy Don; Karen J Wong; Kayhan Garmestani; Luke Park; Chang W Park; Robert W Mallett; Louis J Theodore; Eric K Yau; Thomas Waldmann; Martin W Brechbiel; Chang H Paik; Ira Pastan; Jorge Carrasquillo
Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
Cancer research 2002;62(20):5755-60.
2002: Meili Zhang; Zhengsheng Yao; Kayhan Garmestani; Axworthy Don; Zhuo Zhang; Robert W Mallett; Louis J Theodore; Carolyn K Goldman; Martin W Brechbiel; Jorge Carrasquillo; Thomas Waldmann
Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213.
Blood 2002;100(1):208-16.
2001: Oliver W Press; M Corcoran; Krishnan Subbiah; Donald K Hamlin; D Scott Wilbur; T Johnson; Louis J Theodore; E Yau; Robert W Mallett; Damon L Meyer; Axworthy Don
A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts.
Blood 2001;98(8):2535-43.
2001: SC Goshorn; James Sanderson; Axworthy Don; Yukang Lin; M Hylarides; Jody Schultz
Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy.
Cancer biotherapy & radiopharmaceuticals 2001;16(2):109-23.
2000: Jody Schultz; Yukang Lin; James Sanderson; Yuting Zuo; D Stone; Robert W Mallett; Sibylle Wilbert; Axworthy Don
A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy.
Cancer research 2000;60(23):6663-9.
2000: Axworthy Don; JM Reno; Mark Hylarides; Robert W Mallett; Louis J Theodore; L M Gustavson; F Su; L J Hobson; Paul Beaumier; Alan R Fritzberg
Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(4):1802-7.
2000: Paul L Weiden; Hazel Breitz; Oliver W Press; J W Appelbaum; J K Bryan; S Gaffigan; D Stone; Axworthy Don; D Fisher; JM Reno
Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
Cancer biotherapy & radiopharmaceuticals 2000;15(1):15-29.
2000: Susan J Knox; Michael L Goris; Margaret A Tempero; Paul L Weiden; L Gentner; Hazel Breitz; Gregory P Adams; Axworthy Don; S Gaffigan; K Bryan; Darrell R Fisher; David Colcher; I D Horak; Louis M Weiner
Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):406-14.
2000: Sibylle Wilbert; G Engrissei; E K Yau; David J Grainger; Laurie Tatalick; Axworthy Don
Quantitative analysis of a synthetic peptide, NR58-3.14.3, in serum by LC-MS with inclusion of a diastereomer as internal standard.
Analytical biochemistry 2000;278(1):14-21.
2000: Hazel Breitz; Paul L Weiden; Paul Beaumier; Axworthy Don; C Seiler; F M Su; S Graves; K Bryan; JM Reno
Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000;41(1):131-40.
1999: Scott S Graves; SC Goshorn; D M Stone; Axworthy Don; JM Reno; B Bottino; S Searle; A Henry; J Pedersen; A R Rees; R T Libby
Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(4):899-908.
1998: S Kasina; J A Sanderson; J N Fitzner; A Srinivasan; T N Rao; L J Hobson; JM Reno; Axworthy Don; Paul Beaumier; Alan R Fritzberg
Simplified preformed chelate protein radiolabeling with technetium-99m mercaptoacetamidoadipoylglycylglycine (N3S-adipate).
Bioconjugate chemistry 1998;9(1):108-17.
1990: K J Hoffmann; Axworthy Don; Thomas A Baillie
Mechanistic studies on the metabolic activation of acetaminophen in vivo.
Chemical research in toxicology 1990;3(3):204-11.
1988: Axworthy Don; K J Hoffmann; A J Streeter; C J Calleman; G A Pascoe; Thomas A Baillie
Covalent binding of acetaminophen to mouse hemoglobin. Identification of major and minor adducts formed in vivo and implications for the nature of the arylating metabolites.
Chemico-biological interactions 1988;68(1-2):99-116.
1987: Michael Threadgill; Axworthy Don; Thomas A Baillie; P B Farmer; K C Farrow; A Gescher; P Kestell; P G Pearson; A J Shaw
Metabolism of N-methylformamide in mice: primary kinetic deuterium isotope effect and identification of S-(N-methylcarbamoyl)glutathione as a metabolite.
The Journal of pharmacology and experimental therapeutics 1987;242(1):312-9.
1985: K J Hoffmann; A J Streeter; Axworthy Don; T A Baillie
Identification of the major covalent adduct formed in vitro and in vivo between acetaminophen and mouse liver proteins.
Molecular pharmacology 1985;27(5):566-73.
1985: K J Hoffmann; A J Streeter; Axworthy Don; Thomas A Baillie
Structural characterization of the major covalent adduct formed in vitro between acetaminophen and bovine serum albumin.
Chemico-biological interactions 1985;53(1-2):155-72.
1984: A J Streeter; S M Bjorge; Axworthy Don; Sidney D Nelson; Thomas A Baillie
The microsomal metabolism and site of covalent binding to protein of 3'-hydroxyacetanilide, a nonhepatotoxic positional isomer of acetaminophen.
Drug metabolism and disposition: the biological fate of chemicals 1984;12(5):565-76.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.